Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
NCT ID: NCT00067457
Last Updated: 2015-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
700 participants
INTERVENTIONAL
2003-06-30
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
NCT00067561
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
NCT01855711
Study to Assess the Effect Of Alosetron On Mucosal Blood Flow
NCT00370032
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
NCT01274000
LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT01257477
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
alosetron
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Failed conventional therapy.
* Willing to make daily calls on a touch-tone telephone.
Exclusion Criteria
* Bloody diarrhea, abdominal pain with rectal bleeding.
* Thrombophlebitis.
* Abnormal thyroid stimulating hormone (TSH) value.
* Alcohol and/or substance abuse within past two years.
* Pregnant or lactating.
* History/treatment of malignancy within past five years.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Huntsville, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Pell City, Alabama, United States
GSK Investigational Site
Tallassee, Alabama, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Little Rock, Arkansas, United States
GSK Investigational Site
North Little Rock, Arkansas, United States
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Carlsbad, California, United States
GSK Investigational Site
Concord, California, United States
GSK Investigational Site
Encinitas, California, United States
GSK Investigational Site
Fresno, California, United States
GSK Investigational Site
Garden Grove, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Orange, California, United States
GSK Investigational Site
Roseville, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
San Francisco, California, United States
GSK Investigational Site
Santa Ana, California, United States
GSK Investigational Site
Spring Valley, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Van Nuys, California, United States
GSK Investigational Site
Centennial, Colorado, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Littleton, Colorado, United States
GSK Investigational Site
Longmont, Colorado, United States
GSK Investigational Site
Bristol, Connecticut, United States
GSK Investigational Site
Belleair Bluffs, Florida, United States
GSK Investigational Site
Boca Raton, Florida, United States
GSK Investigational Site
Bradenton, Florida, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
DeLand, Florida, United States
GSK Investigational Site
Gainesville, Florida, United States
GSK Investigational Site
Hollywood, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Kissimmee, Florida, United States
GSK Investigational Site
Melbourne, Florida, United States
GSK Investigational Site
North Miami Beach, Florida, United States
GSK Investigational Site
Spring Hill, Florida, United States
GSK Investigational Site
Stuart, Florida, United States
GSK Investigational Site
Zephyrhills, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Blue Ridge, Georgia, United States
GSK Investigational Site
Dunwoody, Georgia, United States
GSK Investigational Site
Fayetteville, Georgia, United States
GSK Investigational Site
Rome, Georgia, United States
GSK Investigational Site
Savannah, Georgia, United States
GSK Investigational Site
Boise, Idaho, United States
GSK Investigational Site
Coeur d'Alene, Idaho, United States
GSK Investigational Site
Meridian, Idaho, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Libertyville, Illinois, United States
GSK Investigational Site
Moline, Illinois, United States
GSK Investigational Site
Morton Grove, Illinois, United States
GSK Investigational Site
Oakbrook Terrace, Illinois, United States
GSK Investigational Site
Peoria, Illinois, United States
GSK Investigational Site
Rockford, Illinois, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Jeffersonville, Indiana, United States
GSK Investigational Site
Clive, Iowa, United States
GSK Investigational Site
Haysville, Kansas, United States
GSK Investigational Site
Kansas City, Kansas, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Florence, Kentucky, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Madisonville, Kentucky, United States
GSK Investigational Site
Covington, Louisiana, United States
GSK Investigational Site
Lafayette, Louisiana, United States
GSK Investigational Site
Monroe, Louisiana, United States
GSK Investigational Site
New Orleans, Louisiana, United States
GSK Investigational Site
New Orleans, Louisiana, United States
GSK Investigational Site
Shreveport, Louisiana, United States
GSK Investigational Site
Annapolis, Maryland, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Lanham, Maryland, United States
GSK Investigational Site
Oxon Hill, Maryland, United States
GSK Investigational Site
Severna Park, Maryland, United States
GSK Investigational Site
Silver Spring, Maryland, United States
GSK Investigational Site
Towson, Maryland, United States
GSK Investigational Site
Towson, Maryland, United States
GSK Investigational Site
Wheaton, Maryland, United States
GSK Investigational Site
Burlington, Massachusetts, United States
GSK Investigational Site
Farmington Hills, Michigan, United States
GSK Investigational Site
Northville, Michigan, United States
GSK Investigational Site
Petoskey, Michigan, United States
GSK Investigational Site
Saginaw, Michigan, United States
GSK Investigational Site
Brooklyn Center, Minnesota, United States
GSK Investigational Site
Chesterfield, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Lincoln, Nebraska, United States
GSK Investigational Site
Omaha, Nebraska, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Berlin, New Jersey, United States
GSK Investigational Site
Blackwood, New Jersey, United States
GSK Investigational Site
Cedar Knolls, New Jersey, United States
GSK Investigational Site
Oakhurst, New Jersey, United States
GSK Investigational Site
Passaic, New Jersey, United States
GSK Investigational Site
South Bound Brook, New Jersey, United States
GSK Investigational Site
Willingboro, New Jersey, United States
GSK Investigational Site
Albuquerque, New Mexico, United States
GSK Investigational Site
Albany, New York, United States
GSK Investigational Site
Binghamton, New York, United States
GSK Investigational Site
Endwell, New York, United States
GSK Investigational Site
Great Neck, New York, United States
GSK Investigational Site
Pittsford, New York, United States
GSK Investigational Site
Pomona, New York, United States
GSK Investigational Site
Cary, North Carolina, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Gastonia, North Carolina, United States
GSK Investigational Site
Greensboro, North Carolina, United States
GSK Investigational Site
Greenville, North Carolina, United States
GSK Investigational Site
Jacksonville, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Wilmington, North Carolina, United States
GSK Investigational Site
Wilmington, North Carolina, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Bellbrook, Ohio, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Wandsworth, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Tulsa, Oklahoma, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Bensalem, Pennsylvania, United States
GSK Investigational Site
Duncansville, Pennsylvania, United States
GSK Investigational Site
Feasterville, Pennsylvania, United States
GSK Investigational Site
Levittown, Pennsylvania, United States
GSK Investigational Site
Media, Pennsylvania, United States
GSK Investigational Site
Morrisville, Pennsylvania, United States
GSK Investigational Site
Penndel, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Reading, Pennsylvania, United States
GSK Investigational Site
Sellersville, Pennsylvania, United States
GSK Investigational Site
Stoneboro, Pennsylvania, United States
GSK Investigational Site
Anderson, South Carolina, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Summerville, South Carolina, United States
GSK Investigational Site
Sioux Falls, South Dakota, United States
GSK Investigational Site
Bristol, Tennessee, United States
GSK Investigational Site
Clarksville, Tennessee, United States
GSK Investigational Site
Jackson, Tennessee, United States
GSK Investigational Site
Johnson City, Tennessee, United States
GSK Investigational Site
Kingsport, Tennessee, United States
GSK Investigational Site
Knoxville, Tennessee, United States
GSK Investigational Site
Memphis, Tennessee, United States
GSK Investigational Site
Nashville, Tennessee, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Conroe, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Humble, Texas, United States
GSK Investigational Site
North Richland Hills, Texas, United States
GSK Investigational Site
Pasadena, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Sugar Land, Texas, United States
GSK Investigational Site
The Woodlands, Texas, United States
GSK Investigational Site
Salt Lake City, Utah, United States
GSK Investigational Site
Chesapeake, Virginia, United States
GSK Investigational Site
Christiansburg, Virginia, United States
GSK Investigational Site
Danville, Virginia, United States
GSK Investigational Site
Norfolk, Virginia, United States
GSK Investigational Site
Norfolk, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Virginia Beach, Virginia, United States
GSK Investigational Site
Weber City, Virginia, United States
GSK Investigational Site
Bellevue, Washington, United States
GSK Investigational Site
Gig Harbor, Washington, United States
GSK Investigational Site
Lacey, Washington, United States
GSK Investigational Site
Tacoma, Washington, United States
GSK Investigational Site
La Crosse, Wisconsin, United States
GSK Investigational Site
Madison, Wisconsin, United States
GSK Investigational Site
Nedlands, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S3B30048
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.